Summary Phospholipid metabolism of human breast cancer was studied by 31p magnetic resonance spectroscopy (MRS). In vivo localised 31p MR spectra were obtained from the tumour alone using phase modulated rotating frame imaging. For 31 tumours, median (range) phosphomonoester (PME) to ATP ratio was 1.48 (0.57-3.78) and phosphodiester (PDE) to ATP ratio was 1.65 (0.44-3.89). DNA index and S phase fraction (SPF) were measured by flow cytometry of paraffin embedded tissue. Twelve (39%) tumours were diploid and 19 aneuploid. Median (range) SPF for 29 assessable tumours was 5.3% (0.6-28%), with significantly greater median SPF for aneuploid tumours (9.3%) than diploid (3.8%, P = 0.007). There was a significant association between PME/ATP and SPF (P= 0.03) due to a significant correlation for aneuploid tumours (P= 0.01). High resolution 31P MRS of extracts from 18 tumours (including seven studied in vivo) demonstrated that the PME peak consists predominantly of phosphoethanolamine (PE) with a smaller contribution from phosphocholine (PC) (median (range) PE/PC: 3.02 (1.13-5.09)). Changes in PME/ATP were observed for two tumours where tamoxifen stablised disease and may be consistent with the cytostatic effects of this drug.
Breast cancer is the commonest cancer in women with an annual mortality rate in the United Kingdom of over 14,000 (OPCS Monitor, 1992) , and its incidence appears to be rising in the western hemisphere (Glass & Hoover, 1990) . Reduction in mortality has been reported for mammographic screening (Shapiro et al., 1982; Tabar et al., 1985) and adjuvant chemotherapy (Early Breast Cancer Trialists' Col- laborative Group, 1992a,b) . However, many patients with early breast cancer will relapse with metastatic disease and about 20% of women present with locally advanced disease. There is an array of treatment options including endocrine therapy, cytotoxic chemotherapy and radiotherapy. The choice of treatment can be guided by prognostic markers, but assessment of response based on measurement of tumour size is often delayed, and consequently patients experience toxicity from ineffective treatment. 31p Magnetic Resonance Spectroscopy (MRS) may be able to monitor biochemical changes and offers the potential for early prediction of treatment response and disease relapse. It may also be useful in assessing biochemical effects of new antitumour agents that are not directly cytotoxic.
31p MRS provides information on phospholipid metabolism, cellular energetics and intracellular pH. Studies of a wide range of human tumours in comparison with normal tissue demonstrate raised phosphomonoesters (PME) (Oberhaensli et al., 1986; Cadoux-Hudson et al., 1989) . Serial 31p MRS studies in a patient with locally advanced breast cancer demonstrated a reduction in the level of PME in response to tamoxifen and cytotoxic chemotherapy (Glaholm et al., 1989) . In another report of three patients with locally advanced breast tumours, PME/ATP decreased in response to therapy (Ng et al., 1989) . PC and PE are intermediates in membrane phospholipid biosynthesis and can also be generated by growth factor signalling (Fisher et al., 1991) . The concentration of PME may reflect the rate of cell membrane synthesis and therefore cellular proliferation . This is consistent with the observation of high concentration of the phosphomonoester, PE in the developing infant brain (Hope et al., 1984; Younkin et al., 1984) and liver (Moorcroft et al., 1991) , and is further supported by the increase in PME to ATP ratio during liver regeneration in the rat following 70% resection (Murphy et al., 1992) . However, alteration in PME associated with therapy could also be explained by a change in cellular number, particularly as in most cases there was an associated change in tumour size. The biochemical basis for therapy induced changes in PME in human breast cancer detected by 31p MRS is not clear. (Leake et al., 1981) and epidermal growth factor receptor (EGFr) by the radioligand binding assay (Nicholson et al., 1988 (Styles, 1988) . Subjects were positioned supine and slightly rotated to one side so that the tumour was within the homogeneous region of the magnet. The magnetic field homogeneity was optimised by observing the proton signal from the region of breast to be studied. Depth resolved spectra were obtained from the tumour separate from the underlying chest wall muscle using Phase Modulated Rotating Frame Imaging (PMRFI) as originally proposed by Hoult (1979) (Styles, 1991) . From the resulting 2-D data set, tumour spectra were selected by the presence of PME (undetectable in muscle) and summed to maximise signal to noise. A frequency domain, Lorentzian line fitting routine (developed by Counsell C., MRC Radiobiology Unit, Chilton) was used to measure the area of the peaks in the 31p MR spectrum after optimising the baseline fit using polynomial corrections. A mean of three fits was used to calculate PME relative to ATP using the ATP Zy-P signal as the ATP P-P peak was distorted by off resonance effects (Blackledge & Styles, 1988 sharpen the spectral lines, and the sample recentrifuged. The supernatant was lyophilised to dryness overnight. The resulting solid was resuspended in 3 ml of double distilled water, centrifuged to remove residual chelex 100, and adjusted to pH 8.0-8.5 as there was little variation in chemical shift in this range of pH.
Fully relaxed 31P MR spectra were obtained on a 9.4 Tesla magnet, with a repetition time 10 s, sweep width 8064 Hz and 8K data points. Composite pulse proton decoupling was applied during acquisition (power 3 watts), and gated off during the relaxation delay to avoid distortion of spectral intensity by nuclear Overhauser effects. The number of transients accumulated to achieve good signal to noise varied with weight of tumour sample. A coaxial capillary containing methylene diphosphonate acted as a concentration standard. Chemical shifts were referred to glycerophosphocholine at 2.90 ppm (relative to PCr at 0 ppm) as this resonance is virtually unaffected by pH or ionic strength changes and was usually present in the breast tumour extracts. Peak assignments were made on the basis of well established literature on 31P MR spectra from perchloric acid extracts (Evanochko et al., 1984; Murphy, 1989) and confirmed by the addition of known compounds.
DNA flow cytometry Proliferation was evaluated for all untreated breast tumours studied by 31P MRS and normal breast tissue from reduction mammoplasty cases. Flow cytometry was performed on nuclear suspensions prepared form formalin fixed paraffin embedded sections as described previously (Camplejohn et al., 1989) . Fifty lim sections were dewaxed and rehydrated through a series of alcohols into double distilled water. Nuclei were extracted by the addition of pepsin (5 mg ml-) at 37°C for 30 min at pH 1.5. Following filtration through a 35 mm pore size nylon filter and incubation with 1 g ml-I DAPI (4'6-diamidino-2-phenylindol-dihydrochloride), the samples were anlaysed using a Becton Dickinson FACS Analyser powered by a mercury arc lamp. 105 particles were scanned to construct a DNA histogram. DNA index was calculated by relating DNA content of the aneuploid GO/GI peak to that for the diploid GO/GI peak. The SPF for diploid tumours was neasured using the method of Baisch et al. (1975) . The number of cells in S phase was calculated from a rectangle fitted between the peak channels of the GO/GI and G2/M peaks. For the DNA aneuploid histogram, the percentage of aneuploid S phase cells as a percentage of total aneuploid cells was estimated in a similar way (Camplejohn et al., 1989) .
Statistical analysis Non parametric tests, Mann Whitney, Kendall Rank correlation coefficient and Chi squared were used as appropriate.
Results

31P MRS in vivo
Interpretable in vivo 31p MR spectra were obtained from 31/57 (54%) breast tumours studied prior to surgery. The patient characteristics are listed in Table I . Inadequate signal to noise and/or spatial resolution prevented analysis in 26 tumours. About one third of tumours (9/26) were less than 2cm in diameter. Figure 1 shows a typical contour plot where the contour lines represent intensity levels of the 31P MR signal. The tumour at the front of the spectroscopic image contains high levels of PME and PDE. There is no detectable PCr. In contrast, the muscle at the back of the image contains PCr, ATP and Pi. The median PME/yATP was 1.48 (range: 0.57-3.78) and median PDE/yATP was 1.65 (range: 0.44-3.89). Figure 2 shows a typical in vivo 31P MR spectrum from normal breast. In all cases, there was very poor signal to 5.3% (0.6-28%) 3.8% (1.3-6.5%) 9.4% (0.6-28%) noise indicating that the total level of phosphorus-containing metabolites was much lower than in breast cancer.
31P MRS in vivo and tumour proliferation DNA histograms could be interpreted for 29 tumours (coefficient of variation >8% for excluded cases). Twelve (39%) were diploid and 19 aneuploid. The median (range) SPF for all tumours was 5.3% (0.6-28%). The median (range) SPF for aneuploid tumours (9.3% (0.6-28%)) was significantly higher than for diploid tumours (3.8% (1.3 -6.5%)) (P= 0.007). DNA histograms could be evaluated for 6/8 normal breast. All were diploid and the median (range) SPF was 1.4% (1.0-1.8%). The median SPF for normal breast was significantly lower than for both diploid (P = 0.007) and aneuploid tumours (P = 0.0005).
There was a significant association between PME/yATP and SPF (P = 0.03) for all tumours (Figure 3a) due to a significant relationship for the aneuploid tumours (P = 0.01) (Figure 3b) . No relationship between SPF and PME/yATP was observed for diploid tumours (Figure 3c ). Some diploid tumours with low SPF values had moderate PME/yATP ratios. No significant association was found between the relative level of PME and DNA ploidy (P = 0.39).
31P MRS in vivo and other presentation features Median tumour diameter was 3.0 cm (range 1.5-15 cm) ( between PME/yATP and the level of EGFr (P = 0.75) or EGFr status (P = 0.14).
31P MRS in vivo and the effect of tamoxifen Serial 31P MRS studies were not evaluable for 14/17 patients due to poor signal to noise for seven tumours, inadequate localisation for five tumours, and refusal for repeat studies for two patients. The results for three patients with evaluable long term 31P MRS studies are presented.
Case 1 A 82 year old woman presented with tumour measuring 6 x 6 cm in the upper part of the right breast. There was attachment to skin and no sign of fixation to pectoralis major. There was an enlarged right axillary lymph node. 31P MRS was performed the day before starting tamoxifen, at 7 days when no change in tumour size was detected, and at 42 days when progressive tumour not responding to tamoxifen was documented. Tumour size had increased to 7 x 6 cm and there were multiple skin deposits in the outer part of the breast. There was progressive increase in PME/-'ATP from 0.52 at day 0 to 0.80 at day 7 (Figure 4) , and 1.13 at day 42. In addition, there was an improvement in signal to noise.
Case 2 A 71 year old women presented with tumour localised to the upper outer quadrant of the right breast measuring 5 x 4 cm. Tamoxifen for 17 months stabilised tumour size. Serial 31P MRS studies detected progressive reduction in PME/yATP from 2.35 at day 0, to 2.06 at day 86, and 1.27 at day 198. The ratio of PDE/yATP fluctuated from 3.85 at day 0 to 4.90 at day 86, to 1.63 at day 198. At 17 months, the MRS study was uninterpretable due to spectral contamination from underlying chest wall muscle. Localisation was poor for this study. The calculated contribution from muscle to the tumour yATP peak was 64%.
Case 3 A 84 year old woman presented with tumour in the upper part of the right breast measuring 5 x 7 cm. There were no palpable axillary lymph nodes. 31P MRS on day 7 detected an increase in PME/yATP (day 0: 0.29, day 7: 0.59) and PDE/yATP (day 0: 1.07; day 7: 1.47), although there had been no change in tumour size. At day 241, signal to noise in the tumour spectrum was very poor and resonances from PDE and Pi could just be detected, although the tumour was 6 x 6 cm. As the quality of the shimming was similar to the previous MRS studies, the deterioration in the signal to noise was probably due to a reduction in viable tissue within the breast tumour.
31P MRS in vitro and identification ofphosphomonoester Figure 5 shows 31p MR spectra from a human breast cancer in vivo and in vitro. The PME region consists predominantly of phosphoethanolamine (PE) and phosphocholine (PC) with a greater contribution from PE (n = 18, PE/PC: median 3.02, (Hedley et al., 1987; Merkel & McGuire, 1990 ) although this finding is not universal (O'Reilly et al., 1990) . The range of SPF values for diploid tumours (1.6-6.5%) suggests that the majority of cells in these tumours are not proliferating. The G predominant cell population will determine the composition of the 31P MR spectrum. Therefore, a relationship between PME and proliferation would not be detected if the PME content of proliferating cells was not greatly elevated. In support, actively growing human breast cancer cells in cul- ctra in vitro. The concentration of PE inCalculation of total phosphorus in vivo was not appropriate (P = 0.0001) reflecting tumour cellularity.
as the signal to noise often prevented detection of all the om phosphorylated sugars, glycerol-3-phos-ATP peaks and also because the PDE peak contains resonrol-6-phosphate have been observed downances from membrane phospholipids. ) of PE in some 31P MR spectra in vitro.
As cellular ATP is tightly regulated (Neeman & Degani, ATP hydrolysis for all tumours during the 1989), PME relative to ATP may be indicative of intracelbetween surgical excision and freezing the lular levels, particularly as cellularity was highly variable as nitrogen. PME and PDE are stable at room reflected by the wide range of concentrations for PE and PC. up to 90 min (Smith et al., 1991) .
ATP production can be compromised by hypoxia and nutrient deficiency (Freyer et al., 1990) , but for human tumours and tumour proliferation this represents a small proportion of the whole tumour (Sutherland et al., 1988) and would not significantly affect *elationship between DNA ploidy and the the tumour spectrum. relative levels of PE, PC or PE plus PC. For
The increase in PME/yATP for the tumour resistant to icts no relationship was observed between tamoxifen is compatible with an association between PME/ icentration of PE (P = 0.62), PC (P = 0.45) yATP and proliferation. Tamoxifen was associated with P = 0.45). Similarly there was no significant stable disease for the other two cases. liver, the increase in the ratio of PE/PC from 12 h to 48 h following partial hepatectomy appears to be mediated by growth factor signalling as there was a parallel increase in the second messenger, diacylglycerol (Murphy et al., 1992) . Both PE and PC can be produced by hydrolysis of the membrane phospholipids, phosphatidylethanolamine (Kiss & Anderson, 1989) and phosphatidylcholine (Pelech & Vance, 1989) respectively, by phospholipase C. Hydrolysis of phosphatidylcholine by phospholipase D produces choline and phosphatidic acid which is then cleaved to diacylglycerol. It is not clear if the phospholipase C and phospholipase D pathways are activated together or preferentially (Price et al., 1989) . In human dermal fibroblasts the production of diacylglycerol by EGF occurs primarily by phospholipase C (Fisher et al., 1991) . However, the source of PME in breast tumours is unlikely to be due to cell signalling, as there was no relationship between the pool of PME and EGFr level or status. The role of phospholipid metabolites in cellular signalling is not excluded as the change in pool size is likely to be small, or absent as the fluxes of metabolites in and out of the pool could be in balance.
The presence of high levels of PME in tumours may reflect their role as membrane phospholipid precursors. It has been suggested that the increased demand for membrane synthesis in rapidly dividing cells leads to an increase in the synthetic precursors . The CDP-choline pathway is the predominant route for phosphatidylcholine synthesis in eucaryotic cells (Figure 6 ). Upregulation of choline kinase with increased production of PC (Warden & Friedken, 1985) , the precursor for the rate limiting step in this pathway may account for increased PC in rapidly growing cells. In contrast, the contribution of the CDP-ethanolamine pathway to phosphatidylethanolamine synthesis appears to depend upon the supply of ethanolamine, at physiological levels this route contributes about 30% of synthesis (Miller & Kent, 1986 enzymes (Pelech & Vance, 1984) and appear to be under separate control as the incorporation of '4C-ethanolamine into phospholipid is not directly related to the activity of the enzymes involved (Groener et al., 1979) . Decarboxylation of phosphatidylserine with the production of ethanolamine is known to be an important source of phosphatidylethanolamine (Bishop & Bell, 1988) . Ethanolamine is also produced by base exchange of free serine with the polar head group of phosphatidylethanolamine, the major route for synthesis of phosphatidylserine. High concentrations of ethanolamine are toxic in cellular systems (Kaiho & Mizuno, 1985) and could therefore be disposed of by conversion to PE in the CDPethanolamine pathway.
In summary, this study demonstrates a significant association between the relative level of PME to yATP and proliferation for aneuploid tumours. The PME region contains predominantly PE with a smaller contribution from PC. The presence of these compounds may be a consequence of a shift in the balance of phospholipid metabolism to synthesis with more rapid synthesis in the faster growing tumours. Changes in PME/'yATP observed following tamoxifen may be consistent with the cytostatic effects of this drug. More cases need to be studied but the low success rate here reflects the small numbers of cases in published accounts. 31P MRS may only be applicable for monitoring therapy in large tumours, assessing novel agents and their metabolic effects.
Alteration in membrane composition can occur with malignancy (Bergelson et al., 1970 (Bergelson et al., , 1974 and could influence the levels of phospholipid precursors. We are therefore studying the relationship between PME and membrane phospholipids. 
